AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease

Simon Lovestone; Paul Francis; Iwona Kloszewska; Patrizia Mecocci; Andrew Simmons; Hilkka Soininen; Christian Spenger; Magda Tsolaki; Bruno Vellas; Lars-Olof Wahlund; Malcolm Ward

doi:10.1111/j.1749-6632.2009.05064.x

AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease

Simon Lovestone, Paul Francis, Iwona Kloszewska, Patrizia Mecocci, Andrew Simmons, Hilkka Soininen, Christian Spenger, Magda Tsolaki, Bruno Vellas, Lars-Olof Wahlund, Malcolm Ward

Research output: Chapter in Book/Report/Conference proceeding › Conference paper

169 Citations (Scopus)

Abstract

There is an urgent need for Alzheimer's disease (AD) biomarkers especially in the context of clinical trials. Biomarkers for early diagnosis, disease progression, and prediction are most critical, and disease-modification therapy development may depend on the discovery and validation of such markers. AddNeuroMed is a cross European, public/private consortium developed for AD biomarker discovery. We report here the development and design of AddNeuroMed and the progress toward the development of plasma markers. Despite the obstacles to such markers, we have identified a range of markers including CFH and A2M, both of which have been independently replicated. The experience of AddNeuroMed leads us to three overall conclusions. First, collaboration is essential. Second, design is paramount and combining modalities, such as imaging and proteomics, may be informative. Third, animal models are valuable in biomarker research. Most importantly, we have learned that plasma markers are feasible.

Original language	English
Title of host publication	Unknown
Place of Publication	OXFORD
Publisher	Blackwell Publishing
Pages	36 - 46
Number of pages	11
Volume	1180
ISBN (Print)	978-1-57331-772-6
DOIs	https://doi.org/10.1111/j.1749-6632.2009.05064.x
Publication status	Published - 2009
Event	Conference on Biomarkers in Brain Disease - Oxford, ENGLAND Duration: 26 Jan 2009 → 28 Jan 2009

Publication series

Name	BIOMARKERS IN BRAIN DISEASE

Conference

Conference	Conference on Biomarkers in Brain Disease
City	Oxford, ENGLAND
Period	26/01/2009 → 28/01/2009

Access to Document

10.1111/j.1749-6632.2009.05064.x

Cite this

Lovestone, S., Francis, P., Kloszewska, I., Mecocci, P., Simmons, A., Soininen, H., Spenger, C., Tsolaki, M., Vellas, B., Wahlund, L.-O., & Ward, M. (2009). AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. In Unknown (Vol. 1180, pp. 36 - 46). (BIOMARKERS IN BRAIN DISEASE). Blackwell Publishing. https://doi.org/10.1111/j.1749-6632.2009.05064.x

@inbook{e83f2c8d30ae43a18b39186ceebd9c52,

title = "AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease",

abstract = "There is an urgent need for Alzheimer's disease (AD) biomarkers especially in the context of clinical trials. Biomarkers for early diagnosis, disease progression, and prediction are most critical, and disease-modification therapy development may depend on the discovery and validation of such markers. AddNeuroMed is a cross European, public/private consortium developed for AD biomarker discovery. We report here the development and design of AddNeuroMed and the progress toward the development of plasma markers. Despite the obstacles to such markers, we have identified a range of markers including CFH and A2M, both of which have been independently replicated. The experience of AddNeuroMed leads us to three overall conclusions. First, collaboration is essential. Second, design is paramount and combining modalities, such as imaging and proteomics, may be informative. Third, animal models are valuable in biomarker research. Most importantly, we have learned that plasma markers are feasible.",

author = "Simon Lovestone and Paul Francis and Iwona Kloszewska and Patrizia Mecocci and Andrew Simmons and Hilkka Soininen and Christian Spenger and Magda Tsolaki and Bruno Vellas and Lars-Olof Wahlund and Malcolm Ward",

year = "2009",

doi = "10.1111/j.1749-6632.2009.05064.x",

language = "English",

isbn = "978-1-57331-772-6",

volume = "1180",

series = "BIOMARKERS IN BRAIN DISEASE",

publisher = "Blackwell Publishing",

pages = "36 -- 46",

booktitle = "Unknown",

note = "Conference on Biomarkers in Brain Disease ; Conference date: 26-01-2009 Through 28-01-2009",

}

Lovestone, S , Francis, P, Kloszewska, I, Mecocci, P, Simmons, A, Soininen, H, Spenger, C, Tsolaki, M, Vellas, B, Wahlund, L-O & Ward, M 2009, AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. in Unknown. vol. 1180, BIOMARKERS IN BRAIN DISEASE, Blackwell Publishing, OXFORD, pp. 36 - 46, Conference on Biomarkers in Brain Disease, Oxford, ENGLAND, 26/01/2009. https://doi.org/10.1111/j.1749-6632.2009.05064.x

TY - CHAP

T1 - AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease

AU - Lovestone, Simon

AU - Francis, Paul

AU - Kloszewska, Iwona

AU - Mecocci, Patrizia

AU - Simmons, Andrew

AU - Soininen, Hilkka

AU - Spenger, Christian

AU - Tsolaki, Magda

AU - Vellas, Bruno

AU - Wahlund, Lars-Olof

AU - Ward, Malcolm

PY - 2009

Y1 - 2009

N2 - There is an urgent need for Alzheimer's disease (AD) biomarkers especially in the context of clinical trials. Biomarkers for early diagnosis, disease progression, and prediction are most critical, and disease-modification therapy development may depend on the discovery and validation of such markers. AddNeuroMed is a cross European, public/private consortium developed for AD biomarker discovery. We report here the development and design of AddNeuroMed and the progress toward the development of plasma markers. Despite the obstacles to such markers, we have identified a range of markers including CFH and A2M, both of which have been independently replicated. The experience of AddNeuroMed leads us to three overall conclusions. First, collaboration is essential. Second, design is paramount and combining modalities, such as imaging and proteomics, may be informative. Third, animal models are valuable in biomarker research. Most importantly, we have learned that plasma markers are feasible.

AB - There is an urgent need for Alzheimer's disease (AD) biomarkers especially in the context of clinical trials. Biomarkers for early diagnosis, disease progression, and prediction are most critical, and disease-modification therapy development may depend on the discovery and validation of such markers. AddNeuroMed is a cross European, public/private consortium developed for AD biomarker discovery. We report here the development and design of AddNeuroMed and the progress toward the development of plasma markers. Despite the obstacles to such markers, we have identified a range of markers including CFH and A2M, both of which have been independently replicated. The experience of AddNeuroMed leads us to three overall conclusions. First, collaboration is essential. Second, design is paramount and combining modalities, such as imaging and proteomics, may be informative. Third, animal models are valuable in biomarker research. Most importantly, we have learned that plasma markers are feasible.

UR - http://www.scopus.com/inward/record.url?scp=70449441004&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.05064.x

DO - 10.1111/j.1749-6632.2009.05064.x

M3 - Conference paper

SN - 978-1-57331-772-6

VL - 1180

T3 - BIOMARKERS IN BRAIN DISEASE

SP - 36

EP - 46

BT - Unknown

PB - Blackwell Publishing

CY - OXFORD

T2 - Conference on Biomarkers in Brain Disease

Y2 - 26 January 2009 through 28 January 2009

ER -

AddNeuroMed-The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease

Abstract

Publication series

Conference

Access to Document

Other files and links

Fingerprint

Cite this